Data compiled by Redley Lamar · ChainSifter Intelligence
3Suppliers
8Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
Sionna Therapeutics, Inc. (SION) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
14Total relationships
1Distinct source URLs
6High confidence
0.754Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
We have entered into license agreements with Sanofi and AbbVie, pursuant to which, among other things, we have secured exclusive licenses for certain intellectual property and know-how relating to CF…
Reciprocal relationship from ABBV graph: Reciprocal relationship from SION graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from SION graph: Reciprocal relationship from ABBV g…
SANOFI
SANOFI
90%
We have entered into license agreements with Sanofi and AbbVie, pursuant to which, among other things, we have secured exclusive licenses for certain intellectual property and know-how relating to CF…
Sionna Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
SNYNF
Sanofi
72%
Personnel-related (including stock-based compensation) $ 8,399 $ 3,523 $ 4,876 Professional services & fees 1,749 2,037 (288) Facility and depreciation 488 431 57 Total general and administrative exp…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from SION graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from SION graph: Reciprocal relationship from SNYN…
CF-VERTEX-PHARMACEUTICALS-INC
CF-VERTEX-PHARMACEUTICALS-INC
62%
4 As of March 31, 2026, there was $ 78.3 million of unrecognized stock-based compensation expense for common stock option awards that are expected to be recognized over a weighted average period of 2…
DELAWARE-GENERAL-CORPORATION
DELAWARE-GENERAL-CORPORATION
62%
current and future competitors of their product development efforts; • any delay in our regulatory filings for our product candidates or any other product candidate we may develop, and any adverse de…
LEERINK-PARTNERS-LLC
LEERINK-PARTNERS-LLC
62%
complementary CFTR modulators. The trial will evaluate the safety, tolerability, and PK of varying doses of the dual combinations and will inform selection of a dual combination for further developme…
QUARTERLY-REPORT-EMERGING-GROWTH-COMPANY
QUARTERLY-REPORT-EMERGING-GROWTH-COMPANY
62%
Personnel-related (including stock-based compensation) $ 8,399 $ 3,523 $ 4,876 Professional services & fees 1,749 2,037 (288) Facility and depreciation 488 431 57 Total general and administrative exp…
VERTEX-PHARMACEUTICALS-INC
VERTEX-PHARMACEUTICALS-INC
62%
commercialize, market and sell our current or future product candidates. If we are unable to develop, receive marketing approval for and successfully commercialize our product candidates, or if we ex…
Reciprocal relationship from VRTX graph: Reciprocal relationship from SION graph: Reciprocal relationship from VRTX graph: Reciprocal relationship from SION graph: Reciprocal relationship from VRTX g…
Sionna Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
SION-DEBT-12541
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
SION-DEBT
Debt stack $8.4M
90%
Market cache reports total debt of $8.4M.
Sionna Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Sionna Therapeutics, Inc..
Sionna Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
SION-OWNER-RA-CAPITAL-MANAGEMENT-L-P
RA CAPITAL MANAGEMENT, L.P.
90%
13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 122 tracked holders.
Sionna Therapeutics, Inc. Extended Supply Chain Network
